HeartBeam Partners with Evolve Manufacturing to Build HeartBeam AIMIGoTM 12-Lead 3D Vector Electrocardiogram Device - Seite 2

“With our successful five-phase device technology development project with Triple Ring nearing completion, we are advancing towards pre-commercial production. We believe Evolve’s long standing collaborative relationship with Triple Ring will greatly benefit HeartBeam in expediting technology transfer through commercial production once we have received FDA clearance for AIMIGo, estimated for the first quarter of 2023,” concluded Dr. Vajdic.

“Evolve is excited to partner with HeartBeam to manufacture the integral medical device that is part of their AIMIGo solution for detecting heart attacks outside of a medical setting,” said Noreen King, CEO of Evolve Manufacturing Technologies. “We look forward to providing our manufacturing expertise to the HeartBeam team to help turn their innovative science into a commercial product.”

About Evolve Manufacturing

Evolve Manufacturing provides end-to-end contract manufacturing for medical device and life sciences instrument companies. Based in Silicon Valley, Evolve offers turnkey contract manufacturing for OEMs that need low to medium production volumes coupled with best-in-class guidance and attention. From first article builds to prototypes and clinical units, our dedicated customer teams use DFX methodologies to deliver flawless and consistent product quality and a level of flexibility, agility, and customer care rarely found in medical contract manufacturers. For more information visit www.evolvemfg.com.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.